The Endocrine Society
The latest news from the ENDO Annual Meeting, with physician perspective, researcher interviews and clinician insight on diabetes, thyroid and other endocrine disorders.
Related Articles
The role of GLP1 receptor agonists in adult-onset type 1 diabetes mellitus
Nature Reviews Endocrinology – Adult-onset type 1 diabetes mellitus differs from the early onset form in terms of residual endogenous insulin secretion, comorbidities and baseline…
ESE Talks… Balancing the demands of work and family life. Led by EUWIN. | ESE
Following the success of our previous European Women in Endocrinology (EUWIN) led events, our panel will bring their own personal experiences and guidance to this…
Ageism in rheumatic care may negatively impact older patients’ disease management
Rheumatologists who scored worse on an age-related bias assessment tended to see older patients as “more demanding” and focused on symptom relief rather than disease-modifying…
Obesity as a disease | World Obesity Federation
REFERENCES World Health Organization, 1999. Obesity: Preventing and Managing the Global Epidemic. WHO Technical Report Series 894, Geneva: World Health Organization. Kopelman PG, Finer N.…
Crenessity benefits continue for adults, children with congenital adrenal hyperplasia
SAN FRANCISCO — Adults with congenital adrenal hyperplasia treated with an oral nonsteroidal drug saw continued disease control with reduced daily glucocorticoid doses and other…
Less than 5% of global population meets ideal heart health metrics
The prevalence of ideal CV health metrics varies across populations, but even modest improvement may help mitigate the development of CVD and benefit a variety…
Obesity drugs may raise testosterone in men
SAN FRANCISCO — Incretin-based drugs, such as semaglutide and tirzepatide, are tied to increases in total testosterone and free testosterone for men, researchers reported at…
‘Strong support for change’: Pursuit of independent cardiology board continues
Following the recent denial of an independent cardiology certification board, proponents of the new board and the cardiology community continue to discuss next steps.The pursuit…
Beyond a singular focus on GLP-1: why we need a new nomenclature now
The development of glucagon-like peptide-1 (GLP-1)-based therapies for type 2 diabetes and obesity illustrates a remarkable evolution in scientific understanding and therapeutic innovation.1 As the…
Monoclonal antibody-peptide conjugate demonstrates efficacy as once-monthly treatment for obesity – ADA Meeting News
Researchers, including Ania M. Jastreboff, MD, PhD, detailed the results of a phase 2 study of maridebart cafraglutide for inducing weight loss in adults living…
